Investigational / not FDA-approved

Pinealon

EDR tripeptide (Glu-Asp-Arg) — Khavinson-line; ≠ Epitalon ≠ Vesugen ≠ Prostamax.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. Pinealon is the synthetic tripeptide Glu-Asp-Arg (EDR). PubChem CID 10273502; formula C15H26N6O8 / MW 418.40; CAS 175175-23-2. It is a Khavinson-line short peptide studied mainly in Russian-language aging / hypoxia / neuroprotection models. Pinealon ≠ Epitalon (AEDG); ≠ Vesugen (KED); ≠ Prostamax (KEDP); ≠ Semax / Selank. This drawer marks papers. It is not use advice.

Bottom line

Literature is preclinical and small clinical / observational program papers from the short-peptide bioregulator tradition. Reports include free-radical / viability effects in cells, prenatal hyperhomocysteinemia protection in rat offspring, hypoxia models, and polymorbidity aging series that co-mention multiple peptides. No modern multi-region Phase 3 package is assumed. Refuse anti-aging glow.

Papers

PMID 21978084 — Khavinson / Boldyrev line 2011

Tested: Pinealon increases cell viability via suppression of free radical levels and activating proliferative processes (cellular models).

Does not show: a human anti-aging RCT.

PMID 22567179 — Khavinson 2012

Tested: Pinealon protects rat offspring from prenatal hyperhomocysteinemia.

Does not show: human pregnancy indication.

PMID 18546825 — Kozina 2008

Tested: antihypoxic properties of short peptides (includes Pinealon-class framing among short peptides).

Does not show: Pinealon monotherapy human hypoxia trial.

PMID 25051764 — Demyanenko 2014

Tested: cytokine / caspase-3 regulation in old-rat hypoxia models with Cortexin and Pinealon.

Does not show: Cortexin+Pinealon as an approved combination product internationally.

PMID 26390612 — Katyreva 2015

Tested: synthetic peptides in aging patients with chronic polymorbidity and organic brain syndrome (program series; multi-peptide context).

Does not show: a clean Pinealon-only confirmatory RCT with modern CONSORT standards.

PMID 22117547 — Fedoreyeva 2011

Tested: penetration of short fluorescence-labeled peptides into nuclei and DNA interaction (mechanistic class paper).

Does not show: clinical efficacy.

PMID 23734521 — Artamonova 2012

Tested: peptide correction of neurotic disorders among professional truck-drivers (program clinical framing).

Does not show: regulatory approval outside the study jurisdiction narrative.

PMID 28509493 — Mendzheritsky line 2015 (Pinealon/Cortexin hypoxia-hypothermia aged rats) Tested: Pinealon and Cortexin on behavior/neurochemistry in aged rats under hypoxia/hypothermia. Does not show: human cognitive enhancement proof.

What is not established

Modern pivotal human efficacy for Pinealon. Interchangeability with Epitalon, Vesugen, or Prostamax. Anti-aging or “bioregulator” wellness claims. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

21978084 22567179 18546825 25051764 26390612 22117547 23734521 28509493

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.